[
  {
    "ts": "2025-12-26T04:55:00+00:00",
    "headline": "ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly",
    "summary": "ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced that ABL Bio will receive a USD 40 million upfront payment for the license, research and collaboration agreement for its Grabody platform, and a USD 15 million equity investment from Eli Lilly and Company (\"Lilly\").",
    "url": "https://finance.yahoo.com/news/abl-bio-receives-upfront-payment-045500110.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "033d7bf0-85f0-37b7-86e7-80a1d6eb645d",
      "content": {
        "id": "033d7bf0-85f0-37b7-86e7-80a1d6eb645d",
        "contentType": "STORY",
        "title": "ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly",
        "description": "",
        "summary": "ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced that ABL Bio will receive a USD 40 million upfront payment for the license, research and collaboration agreement for its Grabody platform, and a USD 15 million equity investment from Eli Lilly and Company (\"Lilly\").",
        "pubDate": "2025-12-26T04:55:00Z",
        "displayTime": "2025-12-26T04:55:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/fd0d762dba91683f79cf97df7a9c1ab7",
          "originalWidth": 304,
          "originalHeight": 127,
          "caption": "(PRNewsfoto/ABL Bio, Inc.)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5Cab9tihhIJTizWXuUWumw--~B/aD0xMjc7dz0zMDQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/fd0d762dba91683f79cf97df7a9c1ab7.cf.webp",
              "width": 304,
              "height": 127,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bhqGDf3H9SgPhFG311IMdQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/fd0d762dba91683f79cf97df7a9c1ab7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abl-bio-receives-upfront-payment-045500110.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abl-bio-receives-upfront-payment-045500110.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "298380.KQ"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-26T13:01:29+00:00",
    "headline": "Lilly and Novo Cut GLP-1 Prices as Pill Approvals Expand Access",
    "summary": "US price cuts, Medicare expansion, and new oral GLP-1 approvals reshape the competitive outlook for weight-loss drugs.",
    "url": "https://finance.yahoo.com/news/lilly-novo-cut-glp-1-130129689.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "ca4fdfab-cd9c-305e-a497-1db6d26687e8",
      "content": {
        "id": "ca4fdfab-cd9c-305e-a497-1db6d26687e8",
        "contentType": "STORY",
        "title": "Lilly and Novo Cut GLP-1 Prices as Pill Approvals Expand Access",
        "description": "",
        "summary": "US price cuts, Medicare expansion, and new oral GLP-1 approvals reshape the competitive outlook for weight-loss drugs.",
        "pubDate": "2025-12-26T13:01:29Z",
        "displayTime": "2025-12-26T13:01:29Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/434a82c75d97e3a5a22898838638d64c",
          "originalWidth": 6382,
          "originalHeight": 4786,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Klfzvp39.soPeoaiqKcS3w--~B/aD00Nzg2O3c9NjM4MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/us.finance.gurufocus/434a82c75d97e3a5a22898838638d64c.cf.webp",
              "width": 6382,
              "height": 4786,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/W9CEpukOrGiNcDXN4UIi7Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/434a82c75d97e3a5a22898838638d64c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-novo-cut-glp-1-130129689.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-novo-cut-glp-1-130129689.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]